Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:MBRXNASDAQ:MNPRNASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.28-4.1%$1.28$0.85▼$4.40$40.54M0.2931,765 shs7,471 shsMBRXMoleculin Biotech$0.89-6.4%$0.96$0.40▼$5.12$13.44M1.641.46 million shs355,183 shsMNPRMonopar Therapeutics$35.25-0.6%$37.67$1.72▼$54.30$215.55M1.11359,453 shs12,005 shsVTGNVistagen Therapeutics$2.43+0.8%$2.32$1.90▼$4.21$69.56M0.67170,655 shs118,384 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+0.39%-1.51%-10.49%+36.90%-34.36%MBRXMoleculin Biotech-6.41%-9.17%-16.04%-29.37%-81.95%MNPRMonopar Therapeutics-0.56%-4.47%-17.47%+12.66%+1,021.00%VTGNVistagen Therapeutics+0.83%-7.60%+9.46%-6.90%-40.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.1008 of 5 stars3.52.00.00.02.70.01.3MNPRMonopar Therapeutics2.9492 of 5 stars3.45.00.00.03.02.50.0VTGNVistagen Therapeutics1.9156 of 5 stars0.05.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AMBRXMoleculin Biotech 3.00Buy$6.00574.16% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3356.97% UpsideVTGNVistagen Therapeutics 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MBRX, MNPR, AKTX, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.003/3/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/AVTGNVistagen Therapeutics$698K100.48N/AN/A$2.81 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/AN/AMBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/12/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)VTGNVistagen Therapeutics-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)Latest MBRX, MNPR, AKTX, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q4 2025VTGNVistagen Therapeutics-$0.53N/AN/AN/A$0.18 millionN/A5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AVTGNVistagen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29MBRXMoleculin BiotechN/A2.082.08MNPRMonopar TherapeuticsN/A5.415.41VTGNVistagen TherapeuticsN/A9.359.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%MBRXMoleculin Biotech15.52%MNPRMonopar Therapeutics1.83%VTGNVistagen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%MBRXMoleculin Biotech1.90%MNPRMonopar Therapeutics20.50%VTGNVistagen Therapeutics1.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million16.25 millionNot OptionableMBRXMoleculin Biotech2014.13 million3.86 millionNot OptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableVTGNVistagen Therapeutics4028.86 million28.49 millionOptionableMBRX, MNPR, AKTX, and VTGN HeadlinesRecent News About These CompaniesVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?May 28 at 4:10 AM | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above Fifty Day Moving Average - Time to Sell?May 27 at 4:15 AM | americanbankingnews.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comRenaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)May 8, 2025 | marketbeat.comAlmitas Capital LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)May 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Bought by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comWhy Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%April 8, 2025 | aaii.comVistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call TranscriptFebruary 15, 2025 | msn.comVistaGen’s Earnings Call: Progress and ChallengesFebruary 14, 2025 | tipranks.comVistagen: Pherine Candidate Proof Of Concept Continues With Fifth IndicationFebruary 14, 2025 | seekingalpha.comStemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc SharesFebruary 14, 2025 | gurufocus.comVistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...February 14, 2025 | gurufocus.comQ3 2025 Vistagen Therapeutics Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comVistagen advances Phase 3 SAD trials with 2025 data readout targetFebruary 13, 2025 | msn.comVistagen reports Q3 EPS (46c) vs (22c) last yearFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net lossFebruary 13, 2025 | msn.comVistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue EstimatesFebruary 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, MNPR, AKTX, and VTGN Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.28 -0.06 (-4.12%) Closing price 05/27/2025 03:56 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 05/27/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Moleculin Biotech NASDAQ:MBRX$0.89 -0.06 (-6.41%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$0.90 +0.02 (+1.69%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Monopar Therapeutics NASDAQ:MNPR$35.25 -0.20 (-0.56%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$36.80 +1.55 (+4.40%) As of 05/27/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Vistagen Therapeutics NASDAQ:VTGN$2.43 +0.02 (+0.83%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.44 +0.00 (+0.21%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
